National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents
Carregando...
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER BRAZIL
Autores
FERRAZ, Maria Lucia Gomes
PICCOLI, Leonora de Zorzi
REZENDE, Rosamar
BORBA, Luiz Augusto
PISSAIA JUNIOR, Alcindo
CHEINQUER, Hugo
SILVA, Giovanni Faria
FERREIRA, Paulo Roberto Abrao
VILLELA-NOGUEIRA, Cristiane Alves
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.26, n.4, article ID 102388, 5p, 2022
Resumo
Background and aims: Treatment of hepatitis C with direct antiviral agents (DAA) is associ-ated with almost 95% of sustained virological response. However, some patients need retreatment. In Brazil, it should be done according to the Ministry of Health guidelines, fre-quently updated to include newly available drugs. This study aimed to conduct a national survey about the characteristics and outcomes of retreatment of hepatitis C in previously non-responders to DAAs. Patients and methods: Institutions from all over the country were invited to participate in a national registry for retreatment, including information about clinical and epidemiological characteristics of the patients, type and outcomes of retreatment regimens. Only patients previously treated with interferon-free regimens were included. Results: As previous treatments the distribution was: SOF/DCV (56%), SOF/SIM (22%), 3D (11%), SOF/LED (6%) and SOF/RBV (5%). For retreatment the most frequently used drugs were SOF/GP (46%), SOF/DCV (23%) and SOF/VEL (11%). From 159 patients retreated, 132/159 (83%) had complete information in the registry and among them only seven patients were non-responders (SVR of 94.6%). All retreatments were well tolerated, without any serious adverse events or interruptions. Conclusion: The retreatment of patients previously non-responders to DAAs was associated with high rate of SVR in this sample of Brazilian patients. This finding allows us to conclude that the retreatment options available in the public health system in Brazil are effective and safe and are an important component of the strategy of elimination of hepatitis C in our country. (c) 2022 Sociedade Brasileira de Infectologia.
Palavras-chave
Hepatitis C, Retreatment, DAA, Sustained virological response
Referências
- Benzaken AS, 2019, BRAZ J INFECT DIS, V23, P182, DOI 10.1016/j.bjid.2019.04.010
- Blach S, 2022, LANCET GASTROENTEROL, V7, P396, DOI 10.1016/S2468-1253(21)00472-6
- Bourliere M, 2017, NEW ENGL J MED, V376, P2134, DOI 10.1056/NEJMoa1613512
- Buti M, 2015, J HEPATOL, V63, P1511, DOI 10.1016/j.jhep.2015.08.010
- Costilla V, 2015, CLIN LIVER DIS, V19, P641, DOI 10.1016/j.cld.2015.06.005
- Lobato CMD, 2019, ANN HEPATOL, V18, P849, DOI 10.1016/j.aohep.2019.08.001
- El Kassas M, 2020, INT J INFECT DIS, V96, P367, DOI 10.1016/j.ijid.2020.04.022
- Ferenci P, 2014, NEW ENGL J MED, V370, P1983, DOI 10.1056/NEJMoa1402338
- Jang ES, 2020, GUT LIVER, V14, P775, DOI 10.5009/gnl19260
- Kowdley KV, 2014, NEW ENGL J MED, V370, P222, DOI 10.1056/NEJMoa1306227
- Lawitz E, 2016, HEPATOLOGY, V64, P360, DOI 10.1002/hep.28422
- Lionetti R, 2019, ANN HEPATOL, V18, P434, DOI 10.1016/j.aohep.2018.09.005
- Martin MT, 2021, J HEPATOL, V75, P251, DOI 10.1016/j.jhep.2021.02.024
- Ministerio da Saude Brazil, PROT 150 NICO DIR TE
- Nelson DR, 2015, HEPATOLOGY, V61, P1127, DOI 10.1002/hep.27726
- Pawlotsky JM, 2020, J HEPATOL, V73, P1170, DOI 10.1016/j.jhep.2020.08.018
- Pawlotsky JM, 2019, SEMIN LIVER DIS, V39, P354, DOI 10.1055/s-0039-1687823
- Sarrazin C, 2016, J HEPATOL, V64, P486, DOI 10.1016/j.jhep.2015.09.011
- Shousha HI, 2020, EUR J GASTROEN HEPAT, V32, P1017, DOI 10.1097/MEG.0000000000001612
- Stanciu C, 2021, EXPERT OPIN PHARMACO, V22, P1729, DOI 10.1080/14656566.2021.1921737
- Sulkowski MS, 2014, NEW ENGL J MED, V370, P211, DOI 10.1056/NEJMoa1306218
- WHO, 2021, HEP C KEY FACTS